The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset

Table 1

MET, ESR1, and ESR2 mRNA expressions in patients with breast cancer.

Characteristics	Mean ± SD (range)
MET mRNA expression log intensity	5.61 ± 0.29 (4.96–7.86)
ESR1 mRNA expression log intensity	9.61 ± 2.13 (5.22–13.27)
ESR2 mRNA expression log intensity	5.44 ± 0.15 (4.90–6.28)
Characteristics	n (%)
MET mRNA^†
Low	1087 (57.1)
High	817 (42.9)
ESR1 mRNA^†
Low	713 (37.4)
High	1191 (62.6)
ESR2 mRNA^†
Low	986 (51.8)
High	918 (48.2)
MET/ESR coexpression status
	299 (15.7)
	786 (41.3)
	416 (21.8)
	403 (21.2)
	591 (31.0)
	498 (26.2)
	363 (19.1)
	452 (23.7)

^†Patients with mRNA gene expression equal to or below the mean value were indicated to have “low” expression status, while those with mRNA log intensity greater than the mean value were set to have “high” expression status. n(%); frequency and valid percentage.